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PreviewsSUMOylation and PPARγ:
Wrestling with inflammatory signaling
The molecular mechanisms whereby PPARγ inhibits inflammatory gene expression in macrophages are poorly understood.
In a recent Nature paper, Pascual et al. (2005) provide a new model for trans-repression in which ligand-dependent
SUMOylation of PPARγ results in its recruitment to the promoters of inflammatory genes where it inhibits transcription by
preventing clearance of corepressor complexes.Studies over the last decade have iden-
tified members of the nuclear receptor
superfamily of transcription factors as
important regulators of gene expression
in macrophages. Given the established
and emerging roles for macrophages in
metabolic diseases, including athero-
sclerosis and diabetes, the ability to tar-
get macrophage gene expression using
nuclear receptor ligands has suggested
new strategies for intervention in such
disorders. For example, the observa-
tions that synthetic agonists for PPARs
and LXRs reduce atherosclerosis in mice
have stimulated widespread interest in
these receptors as potential targets for
cardiovascular therapeutics (Castrillo and
Tontonoz, 2004). In addition to exerting
beneficial effects on macrophage lipid
metabolism, nuclear receptors such as
PPARγ (Jiang et al., 1998; Ricote et al.,
1998), PPARα (Staels and Fruchart,
2005), PPARδ (Lee et al., 2003), and LXR
(Joseph et al., 2003) have also been re-
ported to attenuate the inflammatory
component of atherosclerosis by inhibit-
ing the production of inflammatory me-
diators. A recent Nature study from Pas-
cual et al. (2005) has provided new
insight into potential mechanisms whereby
nuclear receptors exert these effects.
The authors propose that ligand-depen-
dent SUMOylation directs PPARγ to the
promoters of inflammatory genes where
it inhibits transcription by stabilizing co-
repressor complexes.
The inhibitory action of nuclear recep-
tors on inflammatory pathways has been
best studied in the case of the glucocor-
ticoid receptor (GR). Antagonism of the
NF-κB and AP1 signaling pathways by
GR occurs by several distinct mecha-
nisms, including direct interactions with
p65 and cJun, competition for limited
amounts of transcriptional coactivators,
chromatin remodeling, and by induction
of the NF-κB inhibitor, IκB (Smoak and
Cidlowski, 2004). In contrast to GR, the
mechanism whereby RXR heterodimeric
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ation is less clear. Although significant
ontroversy exists in the literature and
everal distinct hypotheses have been
roposed, the preponderance of evi-
ence points to intranuclear crosstalk
etween PPARγ and transcription fac-
ors such as NF-κB on the promoters
f inflammatory genes, a phenomenon
nown as trans-repression.
In their recent work, Pascual et al.
2005) propose a novel and provocative
echanism to explain how PPARγ trans-
epresses inflammatory gene expression
n macrophages. The authors started
rom the longstanding observation that
nduction of iNOS expression by LPS is
ttenuated by PPARγ agonists. Using a
ombination of siRNA and ChiP meth-
dology they demonstrated that in the
asal state transcription of iNOS is re-
ressed by a complex that contains
BL1, TBLR1, NCoR, and HDAC3. LPS
timulation was shown to causes a rapid
learance of NCoR and HDAC3 from the
romoter by a ubiquitin-dependent mech-
nism and the replacement of these co-
epressor complexes with coactivator
omplexes. When the cells were treated
ith LPS in the presence of a PPARγ ag-
nist, however, PPARγ was recruited to
he iNOS promoter, and NCoR and
DAC3 were not cleared. Recruitment
f PPARγ to the iNOS promoter was not
ependent on sequence-specific DNA
inding, since a PPARγ DNA binding
utant was also recruited and still inhib-
ted iNOS expression. Surprisingly, re-
ruitment of PPARγ to the iNOS pro-
oter was inhibited when expression of
he corepressor NCoR was reduced by
iRNA. Similar effects were observed for
our additional LPS-responsive genes
ndicating that this phenomenon of
CoR-dependent PPARγ recruitment is
ot specific for the iNOS promoter.
The involvement of NCoR in trans-
epression by PPARγ presents an appar-
nt paradox. On the one hand, ligand-
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oters and repression of LPS-respon-
ive genes requires NCoR, but on the
ther hand, ligand binding to PPARγ has
een shown previously to disrupt PPARγ/
CoR interactions and result in PPARγ
arget gene induction. Pascual et al.
2005) hypothesized that PPARγ/NCoR
nteractions during trans-repression were
istinct from the NcoR interactions that
ccur during activation and that another
actor may be involved. They carried out
yeast two-hybrid screen and identified
rotein inhibitor of activated stat 1
Pias1) as a PPARγ interacting protein.
s its name suggests, Pias1 was iden-
ified in a screen for inhibitors of Stat1
ignaling and has been since shown to
e a repressor of the interferon-γ and
F-κB signaling pathways (Liu et al.,
004, 2005). Pias1 also belongs to the
UMO E3 ligase family and is able to
UMOylate target proteins (e.g., P53).
ascual et al. (2005) show that PPARγ
nd Pias1 physically interact and that
nocking down Pias1 abolishes the li-
and-dependent recruitment of PPARγ
o the iNOS promoter and trans-repres-
ion. Knocking down the rate limiting E2
UMO ligase, Ubc9, has a similar effect.
Does SUMOylation of PPARγ explain
ts ability to trans-repress inflammatory
enes? PPARγ contains two SUMOyla-
ion sites (K77 and K365). The SUMO-
lation of K77 has been previously dem-
nstrated to inhibit PPARγ-dependent
ene induction but to have no effect on
rans-repression. In stark contrast, Pas-
ual et al. (2005) found that mutation of
365 eliminated the ability of agonist-
ctivated PPARγ to repress iNOS and to
e recruited to its promoter. How does
odification of PPARγ by SUMOylation
xert this effect? One possibility that the
uthors propose is that ligand-depen-
ent SUMOylation of PPARγ strengthens
ts direct interaction with NCoR and pre-
ents its clearance, thus maintaining a273
P R E V I E W SFigure 1. A model for PPARγ-mediated trans-repression of iNOS expression
A) LPS stimulation promotes the ubiquitin-dependent proteasomal degradation of corepressor complexes
and their exchange for coactivator complexes resulting in iNOS expression.
B) LPS stimulation in the presence of ligand results in SUMOylation of PPARγ on position K365. SUMOylated
PPARγ interacts with NCoR present in corepressor complexes and prevents the clearance of these complexes,
keeping the promotor in a repressed state.
Adapted from Pascual et al. (2005).
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moters.
These findings have opened the door
to the study of a completely new path-
way for nuclear receptor action. As one
would expect with any new idea, a num-
ber of issues remain to be addressed in
f
t
i
T
S
i
c274uture studies. A basic assumption of
his model (Figure 1) is that ligand bind-
ng enhances the SUMOylation of PPARγ.
he observed effect of ligand on PPARγ
UMOylation, however, is modest and it
s unclear what fraction of PPARγ in the
ell is SUMOylated. Moreover, it remains
N
H
D
U
Lo be established that SUMOylated
PARγ is present in corepressor com-
lexes associated with macrophage in-
lammatory genes. The consequence of
UMOylation of PPARγ at K365 for tran-
criptional activation is also not yet
lear. Are such SUMOylated receptors
till competent to participate in activa-
ion complexes?
The proposed involvement of Pias1 in
he PPARγ trans-repression mechanism
ill also be an interesting area for future
nvestigation. Previous studies impli-
ated Pias1 in the control of a small sub-
et of interferon-γ- and LPS-responsive
enes (Liu et al., 2004, 2005). Such
enes were found to be hyperrespon-
ive to inflammatory induction in Pias1
O macrophages compared to wt con-
rols. Interestingly, however, iNOS ex-
ression was not altered in Pias1 knock-
ut cells. The importance of the E3
UMO ligase activity in Pias1 for its ef-
ects on cell signaling is also not well de-
ined. It is therefore unclear at present
hether the Pias1-dependent regulation
f inflammatory gene expression ob-
erved by Liu et al. (2004, 2005) is re-
ated to the findings of Pascual et al.
2005) on PPARγ repression of iNOS. Ul-
imately, it will be important to address
hether SUMOylation contributes to the
nti-inflammatory effects of PPARγ in
isease contexts such as atherosclero-
is and inflammatory bowel disease. A
nockin of the K365R mutant into the
PARγ locus would be predicted to
bolish the anti-inflammatory action of
PARγ ligands in these settings.
A particularly interesting question is
hether the model of Pascual et al.
2005) is a general mechanism that also
overns the trans-repression of inflam-
atory gene expression by other nu-
lear receptors. The fact that LXRs,
PARγ, and GR repress an overlapping
et distinct set of inflammatory genes
Ogawa et al., 2005) suggests a high de-
ree of complexity in the mechanisms
hat control trans-repression. SUMOyla-
ion may be a key part of this regula-
ory network.
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